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SUMMARY The aim of the present study was to
investigate whether removal of all amalgam ﬁllings
was associated with long-term changes in health
complaints in a group of patients who attributed
subjective health complaints to amalgam ﬁllings.
Patients previously examined at the Norwegian
Dental Biomaterials Adverse Reaction Unit were
included in the study and assigned to a treatment
group (n = 20) and a reference group (n = 20). Par-
ticipants in the treatment group had all amalgam
ﬁllings replaced with other restorative materials.
Follow-ups took place 3 months, 1 and 3 years after
removal of all amalgam ﬁllings. There was no
intervention in the reference group. Subjective
health complaints were measured by numeric rating
scales in both groups. Analysis of covariance was
used to compare changes in health complaints over
time in the two groups. In the treatment group,
there were signiﬁcant reductions in intra-oral and
general health complaints from inclusion into study
to the 3-year follow-up. In the reference group,
changes in the same period were not signiﬁcant.
Comparisons between the groups showed that
reductions in intra-oral and general health com-
plaints in the treatment group were signiﬁcantly
different from the changes in the reference group.
The mechanisms behind this remain to be identiﬁed.
Reduced exposure to dental amalgam, patient-
centred treatment and follow-ups, and elimination
of worry are factors that may have inﬂuenced the
results.
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Introduction
For decades, dental amalgam has been extensively
used in the treatment of caries lesions. Dental amal-
gam consists of approximately 50% metallic mercury
mixed with an alloy mainly consisting of silver, tin
and copper (1). The safety of dental amalgam has
been questioned, and it has been discussed to what
extent mercury released from amalgam ﬁllings may
lead to adverse health effects (2–8). Generally, no
deleterious effects from amalgam are detected in
studies on samples of the general population (5,
9–11), and no adverse reactions could be detected in
two randomised controlled studies on school children
treated with dental amalgam (3, 4). Dental amalgam
ﬁllings release elemental mercury vapour in the
mouth, resulting in elevated concentrations of mer-
cury in blood, plasma and urine, and concentration of
inorganic mercury in the brain (12–19). The possibility
that a small fraction of the population may have
predispositions to rare adverse reactions to dental
amalgam cannot be ruled out; thus, research on
adverse effects associated with exposure to dental
amalgam should focus on the possibility of rare
outcomes (20). People with health complaints
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complaints are caused, or aggravated, by mercury
released from their amalgam ﬁllings. It has been estab-
lished that dental amalgam ﬁllings may lead to local
adverse reactions, including oral lichenoid reactions
(21), and removal of amalgam ﬁllings in contact with
the lesions is generally recommended. However, for a
number of patients, no objective signs of adverse
reactions to amalgam ﬁllings, or other diseases explain-
ing their complaints, can be observed (22). Patients who
attribute subjective health complaints to dental amal-
gam describe a number of health complaints including
tiredness, headaches, pain from muscles and joints, and
problems with memory and concentration (18, 22).
There is a lack of treatment options for patients without
objective signs of adverse reactions to amalgam ﬁllings,
and removal of sound amalgam ﬁllings is generally not
recommended. Some patients nevertheless decide to
remove all amalgam ﬁllings at their own initiative (23),
and studies have reported signiﬁcant improvements
in subjective health complaints after the removal of
amalgam ﬁllings (24, 25).
The aim of the present study was to investigate
whether removal of all amalgam ﬁllings in a group of
patients who attributed subjective health complaints to
dental amalgam (treatment group) was associated with
long-lasting changes in subjective health complaints.
The underlying null hypothesis was that there would be
no signiﬁcant differences in long-term changes in health
complaints between the treatment group and a compa-
rable reference group. In addition, secondary analyses of
changes in health complaints in the treatment group
and the reference group were investigated indepen-
dently, testing the null hypotheses of no changes in
health complaints within each group. Within-group
changes in mercury concentration in serum and urinein
the treatment group were also investigated.
Materials and methods
Design
The study was designed as a before-and-after study
with a comparison group (reference group) comparing
changes in health complaints in a treatment group,
which had all amalgam ﬁllings replaced with other
restorative materials, with changes in health complaints
in a comparable reference group, which did not receive
any intervention.
Participants
Participants were recruited from patients (n = 368)
examined at the Norwegian Dental Biomaterials
Adverse Reaction Unit in the period 1993–1999 (initial
examination; Fig. 1). The majority of the patients had
been referred to the unit because of health complaints
attributed to amalgam ﬁllings (22). Generally, either
the patient or the referring physician ⁄dentist had raised
the question that dental materials could be a causal or
contributing factor related to the patient’s health
problems. In 2000–2001, patients with known
addresses (n = 358) were sent a questionnaire (Ques-
tionnaire 1) regarding current health complaints and
medical and dental treatment since the initial exami-
nation. The questionnaire was returned by 207 patients
(Fig. 1). Based on the responses to the questionnaire,
157 patients did not fulﬁl one or more of the inclusion
criteria listed in Table 1, leaving 50 patients who were
randomly allocated into a treatment group (n = 20), a
reference group (n = 20) and a group of reserves
(n = 10; Fig. 1). The function random number in
Microsoft Excel 97 was used for the allocation. The
exclusion criteria listed in Table 1 were applied to the
treatment group in order to increase the probability of
participants in this group being able to complete the
replacement process. Six participants were excluded
from the treatment group according to these criteria.
The same exclusion criteria were used in the group of
reserves for sequential inclusion into the treatment
group, resulting in four participants not being eligible
for participation in the treatment group. The remaining
six participants from the group of reserves were used to
replace the excluded participants from the treatment
group. The criteria were applied based on clinical
documentation, telephone interviews and a clinical
examination (pre-treatment examination). The exclu-
sion criteria were initially not applied to the reference
group as no intervention was planned for this group.
Initial examination (1993–1999)
At the initial examination at the unit (22), patients
underwent a medical and dental examination. Blood
and urine samples were collected and analysed for
mercury in addition to routine analyses (17). Patients
were also asked to complete questionnaires regarding
suspected adverse reactions to dental materials, current
and previous health complaints and demographic
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at the initial examination neither signs of contact
allergic reactions to dental materials nor a known
history of such reactions and consequently were not
recommended removal of amalgam ﬁllings.
Questionnaire 1 (2000–2001)
Questionnaire 1 included questions regarding current
health complaints, treatment since the initial examina-
tion and demographic variables. Health complaints
were measured by numeric rating scales using numbers
from 0 to 10. No information on a planned intervention
study was given in the questionnaire. Responses to
Questionnaire 1 were used for identifying patients
eligible for participation and as baseline values for
comparisons of changes in health complaints in the
treatment group and the reference group. Questions
from Questionnaire 1 were included in all subsequent
questionnaires.
Initial examination (1993–1999)
n = 368 
Questionnaire 1 (2000–2001)
n = 358 
a
Not included
n = 157 
b
Analysed for changes in health complaints
from Questionnaire 1 to 3 year follow-up:
n = 19
Analysed for changes over time:
n = 18
Treatment group
(amalgam removal) 
n = 20
+10 reserves (see text) 
Reference group
(no intervention)
n = 20
Included
n = 50
Randomly allocated 
Responded to Questionnaire 1
n = 207 
Analysed for changes in health complaints 
from Questionnaire 1 to Questionnaire 3: 
n = 13
Analysed for changes over time:
n = 12
Excluded 
c 
n = 10 
Treatment group
n = 20 
Lost to follow-up:
3 months: n = 1
1 year: n = 0
3 years: n = 1
Responded to:
Questionnaire 2: n = 15
Questionnaire 3: n = 15
Lost to follow-up:
Questionnaire 2: n = 5
Questionnaire 3: n = 5
Excluded from analyses 
d:
Questionnaire 2: n = 1
Questionnaire 3: n = 2
Completed amalgam removal
n = 20
Followed-up at:
3 months: n = 19
1 year: n = 20
3 years: n = 19
Allocation
Follow-up
Analysis
Fig. 1. Participant ﬂow. Flow diagram showing participant ﬂow in the study. The study is a before-and-after study with a comparison
group (reference group).
aCurrent addresses were missing for 10 patients;
bdid not fulﬁl inclusion criteria listed in Table 1;
cexcluded
according to exclusion criteria listed in Table 1;
dremoved all amalgam ﬁllings.
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In September 2002, participants in the treatment group
underwent a pre-treatment examination consisting of
medical and dental examinations and collection of
samples of blood serum and urine. Blood serum was
analysed for mercury concentration by sector ﬁeld
inductively coupled plasma–mass spectrometry (26,
27), while urine was analysed for mercury concentra-
tion by cold vapour atomic absorption spectrometry
(28). Participants also responded to a questionnaire
similar to Questionnaire 1. The pre-treatment exami-
nation and all subsequent follow-ups took place at the
Dental Biomaterials Adverse Reaction Unit. Participants
in the reference group were not assigned any treatment
and were not asked to go through a pre-treatment
examination.
Intervention
The assigned intervention in the treatment group was
removal of all amalgam ﬁllings. The amalgam ﬁllings
were replaced with other dental restorative materials
(e.g. composites, ceramic restorations and metalloce-
ramic crowns). All treatment costs were covered by
project funds. Replacement of amalgam ﬁllings is not
possible to mask, and thus, no blinding was used. The
replacement was carried out by the participants’ own
dentists according to clinical guidelines aiming at
minimal exposure to mercury during removal sessions
(29). The dentists were instructed to use rubber dam,
high-volume suction, water cooling and to remove
ﬁllings in chunks using a sharp dental bur. Eighteen
dentists from 18 different dental practices were in-
volved in the study. One dentist treated three patients;
the other dentists treated one patient each. Participants
were given written instructions to contact the Dental
Biomaterials Adverse Reaction Unit if they experienced
increased health complaints like chills, fever, pain and
rashes in relation to the amalgam replacement process.
These instructions included advice to the patient’s
physician regarding blood tests to be taken (leucocytes,
CRP, IgE and mercury concentration in blood) in case
of increased health complaints after dental treatment.
To compare replacement of amalgam ﬁllings with the
standard treatment (i.e. no amalgam replacement), no
intervention was assigned to the reference group.
Follow-up
Treatment group. Routines for the follow-ups were
similar to the pre-treatment examination. Follow-ups
took place 3 months, 1 and 3 years after completed
replacement of amalgam ﬁllings (Fig. 2). The follow-
ups included control of the new dental restorations by a
dentist, questions about experienced side effects like
post-operative dental pain and other complications, and
collection of serum samples. Urine samples were
Table 1. Eligibility criteria and number of patients not included.
Inclusion criteria were applied based on information from initial
examination and Questionnaire 1. Exclusion criteria were applied
in the treatment group and reserves, and were applied in relation
to the pre-treatment examination in September 2000
Inclusion criteria
Numbers not
fulﬁlling
criterion
†
Referred to the Norwegian Dental
Biomaterials Adverse Reaction Unit
for examination of health
complaints attributed to amalgam
ﬁllings
33
Amalgam ﬁllings still present 79
No diagnosed contact allergy to
substances in resin-based dental
materials
54
Health complaints from at least three
different organ systems
25
Data on mercury in blood and urine
from initial examination
59
Age 25–55 at initial examination 10
Accepted to be contacted in a
follow-up study
11
Exclusion criteria (treatment group
and reserves)
Numbers
excluded
Severe medical disorders (e.g.
multiple sclerosis, ALS, severe
rheumatoid arthritis)
1
Severe food allergies 1
Psychological difﬁculties or
psychiatric disorders that could
inﬂuence the dental treatment
3
Complicated therapy (severe
periodontitis, high caries activity
and ⁄or need for complicated dental
rehabilitation – e.g. bridges)
4
Inclusion criteria no longer fulﬁlled 1
‡
†One hundred and ﬁfty-seven patients did not fulﬁl one or more
of the inclusion criteria.
‡Completed removal of amalgam ﬁllings since responding to
Questionnaire 1.
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interview or health guidance was included.
Reference group. Follow-ups in this group were limited
to questionnaires sent by post. Participants were sent
Questionnaire 2 in 2004 and Questionnaire 3 in 2007.
Questionnaire 2 was given at approximately the same
time as the majority of participants in the treatment
group went through their 1-year follow-up. Question-
naire 3 was given in parallel with the 3-year follow-up
in the treatment group (Fig. 2). Based on available
information from the initial examination and Ques-
tionnaire 1, the exclusion criteria used in the treatment
group were applied post hoc to the reference group,
resulting in two of the initial 20 participants being
excluded. Reasons for exclusion were severe food
allergy and complicated dental treatment (one patient)
and diagnosed contact allergy to substances in resin-
based dental materials (one patient). Results from
comparisons of changes in health complaints in the
treatment group and the reference group were calcu-
lated using both the initial reference group and the
reference group with the two participants excluded
from analyses.
Outcome variables
Primary outcome measures were changes in local oro-
facial complaints and general health complaints from
Questionnaire 1 (inclusion into study) to the 3-year
follow-up in the treatment group and to Questionnaire
3 in the reference group. Current health complaints in
both groups were measured by numeric rating scales
(30) included in the questionnaires. The questionnaires
were given at all measure points. The same scales have
previously been used in a similar patient population (8)
and include 23 items addressing a diverse range of
oro-facial and general health complaints frequently
reported by patients with subjective health complaints
attributed to amalgam ﬁllings. Oro-facial complaints
were categorised as either intra-oral (six items: intra-
oral burning sensation, intra-oral pain ⁄tenderness,
taste disturbances, intra-oral stiffness ⁄paresthesia, dry
mouth and increased salivation ⁄mucus) or extra-oral
(ﬁve items: extra-oral burning sensation, extra-oral
pain ⁄tenderness, extra-oral stiffness ⁄paresthesia, extra-
oral skin problems and pain from temporomandibular
joints). The sum scores for each category were used as
index scores (8). Index scores for general health
complaints (12 items: musculoskeletal complaints, gas-
trointestinal complaints, cardiovascular complaints,
skin problems, complaints related to eyes ⁄sight, com-
plaints related to ears ⁄hearing ⁄nose ⁄throat, tiredness,
dizziness, headaches, memory problems, difﬁculty con-
centrating and anxiety ⁄depression) were constructed in
the same way (8). Highest possible index score was 60
for intra-oral index, 50 for extra-oral index and 120 for
the general health complaints index. Internal consis-
tency for the indices was estimated by Cronbach’s alpha
using the entire group of patients randomised (n = 50;
Fig. 1) and found to be 0Æ66, 0Æ72 and 0Æ80, respectively.
Power calculation
Number of participants included in this study was
limited by available patients. One of the main objectives
of the study was to test the null hypothesis that changes
in index scores for health complaints were equal in the
Q1 Treatment 
group
Reference 
group
Pre-treatment
examination
Treatment
period
Three month
follow-up
One year 
follow-up
Three year
follow-up 
Q2 Q3
2000–2001
Year
Year
Q1
2000–2001
2004 2007
2002 2002–2005 2003–2005 2004–2006 2006–2008
Fig. 2. Timeline for the study. Timeline for the trial for the treatment group and the reference group. Q1, Q2 and Q3 indicate
Questionnaire 1, Questionnaire 2 and Questionnaire 3, respectively. Time frames for the activities are indicated for the treatment group
(top) and the reference group (bottom).
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a mean difference in index score for general health
complaints of 10Æ0 between the groups (corresponding
to a mean difference before–after of 10Æ0 in the
treatment group versus a mean difference of 0Æ0i n
the reference group) and a common within-group
standard deviation of 10Æ0, a sample size of 20 patients
in each group will give the study a power of 87% to
yield a statistically signiﬁcant result. The criterion for
signiﬁcance (alpha) was 0Æ05, and the test was two-
tailed.
Statistical methods
Mean values with 95% conﬁdence intervals and anal-
ysis of variance were used for comparisons between
groups. Paired-sample t-tests and analysis of variance
for repeated measures were used to investigate within-
group changes over time. Variables for changes in
health complaints, from Questionnaire 1 to the 3-year
follow-up in the treatment group and from Question-
naire 1 to Questionnaire 3 in the reference group, were
constructed by subtracting the most recent scores from
the scores from Questionnaire 1. A positive value
indicated a reduction in complaints, whereas a negative
value indicated increased complaints. The primary
hypothesis of changes in reported health complaints
in the treatment group compared with the reference
group was tested by between-group comparisons of
unadjusted pre–post per-protocol changes in the two
groups using independent-sample t-tests. Adjustments
for age, gender, and complaint intensity reported in
Questionnaire 1 were made by analysis of covariance.
We used last value carried forward to replace missing
values for intention-to-treat analysis (ITT). Sample-
Power 2.0* was used for power calculations, and SPSS
15.0* was used for all other statistical analyses. P-values
<0Æ05 were considered statistically signiﬁcant for all
analyses.
Ethical approval and registration
The project protocol was approved by the Regional
Committee for Medical Research Ethics in Western
Norway (REK III, 24.01) and registered at ClinicalTri-
als.gov (NCT00346944). Participants in the treatment
group received information on possible side effects from
new ﬁllings and possible post-operative complications
following replacement of amalgam ﬁllings. Written
consent was obtained from all participants in both
groups.
Results
Participant ﬂow and numbers analysed
Treatment group. All 20 participants in the treatment
group received the assigned intervention (replacement
of all amalgam ﬁllings). One participant could not
attend the 3-month follow-up, and another participant
could not attend the 3-year follow-up. For analysis of
changes in health complaints from Questionnaire 1 to
the 3-year follow-up, data from 19 participants were
analysed (Fig. 1). For repeated measures analysis, data
from 18 participants were analysed (Fig. 1).
Reference group. Questionnaire 2, which was sent to all
20 participants in the reference group in 2004, was
returned by 15 participants. One participant reported
having removed all amalgam ﬁllings between Ques-
tionnaire 1 and Questionnaire 2. Questionnaire 3 was
sent to all 20 participants in the reference group. The
questionnaire was returned by 15 participants (Fig. 1).
For analyses of changes in health complaints from
Questionnaire 1 to Questionnaire 3, data from 13
participants were analysed. For repeated measures
analysis, data from 12 participants were analysed.
Changes in health complaints in the treatment group
were also compared with changes in the reference
group after post hoc application of exclusion criteria
based on data from 12 participants in the reference
group.
Initial examination and Questionnaire 1
Data from the initial examination and Questionnaire 1
were used as baseline values in the study. Number of
amalgam surfaces and concentration of mercury in
blood and urine were not signiﬁcantly different
between the groups at the initial examination
(Table 2). Results from Questionnaire 1 showed that
the ﬁnal treatment group (n = 20) was similar to the
reference group (n = 20) with regard to age, gender
distribution, education level and medication. Levels of
reported intra-oral, extra-oral and general health com-
plaints were slightly lower in the treatment group, but *SPSS Inc., Chicago, IL, USA.
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cally signiﬁcant. The proportion of individuals currently
on sick leave or receiving disability pension was
considerably higher in the group of individuals who
were excluded from the treatment group compared to
the treatment group and the reference group. Partici-
pants’ assessments of risks associated with dental
amalgam were similar across groups (Table 2).
Comparisons of changes in health complaints in the treatment
group and the reference group
Per-protocol comparisons of changes in health com-
plaints, from Questionnaire 1 to the 3-year follow-up in
the treatment group and Questionnaire 3 in the
reference group, showed that changes in mean index
scores for intra-oral and general health complaints were
signiﬁcantly different in the two groups, whereas
changes in extra-oral health complaints were not
signiﬁcantly different (Table 3). After adjusting for
gender, age and complaint intensity reported in Ques-
tionnaire 1, changes in intra-oral and general health
complaints remained signiﬁcantly different, and
changes in extra-oral health complaints remained not
signiﬁcantly different (Table 3). Results from intention-
to-treat comparisons were in general similar to the
results from per-protocol analyses (Table 3). Results
from analyses based on data from the reference group
after post hoc application of exclusion criteria showed no
major differences compared with the analyses using all
13 participants from the initial reference group. Unad-
justed per-protocol differences in changes in index
scores between the treatment group and the reference
group after application of exclusion criteria were 8Æ3
(95% CI: 1Æ2t o1 5 Æ3, P =0 Æ024), 3Æ6 (95% CI: )3Æ7t o
10Æ7, P =0 Æ320) and 19Æ9 (95% CI: 8Æ1t o3 1 Æ7, P =
0Æ002) for the intra-oral, extra-oral and general indices,
respectively.
Table 2. Descriptive background data. Background data for the treatment group, the reference group and for patients excluded from the
treatment group. Data obtained at the initial examination and from Questionnaire 1 (Q1)
Treatment
group
(n = 20)
Reference
group
(n = 20)
Excluded from
treatment
group (n = 10) Data from
Women, n (%) 14 (70) 16 (80) 8 (80)
Age (years) in September 2000, mean (s.d.) 46Æ9( 6 Æ7) 44Æ7( 6 Æ5) 52Æ6( 7 Æ0)
Education (years), mean (s.d.) 11Æ5( 3 Æ6) 11Æ3( 2 Æ8) 10Æ3( 2 Æ6) Initial ex.
Reported smoking at initial examination, n (%) 4 (20) 7 (35) 3 (30) Initial ex.
On sick leave or disability pension, n (%) 9 (45) 7 (35) 9 (90) Q1
Regular dental care, n ⁄valid n
† (%) 17 ⁄18 (94) 20 ⁄20 (100) 6 ⁄7 (86) Q1
Used medication last 12 months, n (%)
Analgesics 13 (65) 13 (65) 7 (70) Q1
Antidepressants 6 (30) 3 (15) 2 (20)
Vitamins ⁄dietary supplements 13 (65) 13 (65) 8 (80)
Participants’ assessments of risks associated with dental amalgam, n (%)
Very high 17 (85) 15 (75) 10 (100) Q1
Medium 3 (15) 4 (20) –
Low – – –
Very low – – –
Missing – 1 (5) –
Number of amalgam surfaces, mean (s.d.) 36Æ8 (11Æ1) 38Æ0 (11Æ3) 27Æ2 (16Æ3) Initial ex.
Concentration of mercury, mean (s.d.)
Blood (nmol L
)1)2 3 Æ5 (10Æ4) 27Æ5 (12Æ5) 33Æ0 (22Æ1) Initial ex.
Urine (nmol L
)1)2 4 Æ0 (17Æ6) 22Æ0 (16Æ4) 21Æ0 (19Æ7)
Urine (nmol per mmol creatinine) 2Æ7( 1 Æ9) 2Æ6( 2 Æ7) 2Æ4( 2 Æ3)
Self-reported health complaints, mean (s.d.)
Intra-oral index 8Æ4( 6 Æ6) 13Æ0 (12Æ0) 11Æ2( 7 Æ2) Q1
Extra-oral index 6Æ9( 8 Æ4) 11Æ0( 9 Æ3) 9Æ2( 8 Æ0)
General index 41Æ5 (16Æ0) 47Æ3 (21Æ2) 42Æ3 (15Æ0)
†Five patients did not answer the question but had started removal of amalgam restorations.
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In the treatment group, there were signiﬁcant reduc-
tions in mean index scores for intra-oral and general
health complaints from Questionnaire 1 to the 3-year
follow-up (Table 3). The reduction in mean index
scores for extra-oral health complaints in this period
was not signiﬁcant. Intention-to-treat analysis showed
similar results as the per-protocol analysis (Table 3). In
the repeated measures analysis (Table 4), data from the
pre-treatment examination and all follow-ups were
included. Per-protocol repeated measures analysis
showed signiﬁcant overall effects of time for all three
index scores. Plots of intra-oral, extra-oral and general
index scores from Questionnaire 1 against index scores
at 3-year follow-up are given in Fig. 3.
Changes in health complaints in the reference group
In the reference group, there was a slight, but not
statistically signiﬁcant, increase in mean index scores
for intra-oral, extra-oral and general health complaints
from Questionnaire 1 to Questionnaire 3 (Table 3).
Intention-to-treat analysis showed no signiﬁcant
changes in mean index scores from Questionnaire 1
to Questionnaire 3 (Table 3). Data from Questionnaire
2 were included in the repeated measures analysis
(Table 4). Per-protocol analysis of changes in mean
index scores over time showed a signiﬁcant overall
effect of time for general health complaints. Plots of
intra-oral, extra-oral and general index scores from
Questionnaire 1 against index scores from Question-
naire 3 are given in Fig. 3.
Table 3. Comparisons of changes in health complaints in the treatment group and the reference group. Per-protocol (PP) and intention-
to-treat (ITT) comparisons of changes in health complaints from Questionnaire 1 to the 3-year follow-up in the treatment group and
Questionnaire 3 in the reference group. Mean changes in index scores and mean differences in changes in index scores (mean changes in
the treatment group minus mean changes in the reference group) are given
n
Difference
Questionnaire 1- to
3-year follow-up
†
Unadjusted differences in
changes in index scores
‡
Adjusted difference in changes in
index scores
§
Mean
¶ 95% CI Mean 95% CI P-value* Mean 95% CI P-value*
Intra-oral index
Treatment group (PP) 19 3Æ70 Æ5t o6 Æ9
Reference group (PP) 13 )4Æ2 )11Æ6t o3 Æ1
Treatment–reference (PP) 7Æ91 Æ1t o1 4 Æ70 Æ024 8Æ11 Æ9t o1 4 Æ20 Æ012
Treatment group (ITT) 20 3Æ50 Æ4t o6 Æ6
Reference group (ITT) 20 )0Æ6 )6Æ4t o5 Æ2
Treatment–reference (ITT) 4Æ1 )2Æ3t o1 0 Æ50 Æ200 6Æ91 Æ3t o1 2 Æ40 Æ016
Extra-oral index
Treatment group (PP) 19 1Æ5 )2Æ8t o5 Æ8
Reference group (PP) 13 )1Æ8 )7Æ9t o4 Æ3
Treatment–reference (PP) 3Æ2 )3Æ7t o1 0 Æ20 Æ346 5Æ5 )0Æ4t o1 1 Æ40 Æ066
Treatment group (ITT) 20 2Æ0 )2Æ2t o6 Æ2
Reference group (ITT) 20 )0Æ6 )4Æ8t o3 Æ6
Treatment–reference (ITT) 2Æ6 )3Æ1t o8 Æ30 Æ365 4Æ3 )1Æ6t o1 0 Æ30 Æ145
General index
Treatment group (PP) 19 9Æ74 Æ4t o1 5 Æ0
Reference group (PP) 13 )8Æ7 )21Æ4t o4 Æ0
Treatment–reference (PP) 18Æ46 Æ8t o3 0 Æ00 Æ003 17Æ45 Æ8t o2 9 Æ00 Æ005
Treatment group (ITT) 20 10Æ15 Æ0t o1 5 Æ2
Reference group (ITT) 20 )2Æ3 )13Æ1t o8 Æ5
Treatment–reference (ITT) 12Æ40 Æ9t o2 3 Æ90 Æ036 14Æ22 Æ4t o2 6 Æ00 Æ020
*Level of signiﬁcance: P <0 Æ05.
†For the reference group, data from Questionnaire 3 were used.
‡Independent-sample t-test comparing changes in index scores in the treatment group and the reference group.
§Analysis of covariance of changes in index scores in the treatment group and the reference group, adjusted for gender, age and health
complaints from Questionnaire 1.
¶Positive values indicate reduced health complaints, and negative values indicate increased health complaints.
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There was a signiﬁcant decrease in mercury concentra-
tion in serum and urine following the removal of
amalgam ﬁllings. After removal of the ﬁllings, the mean
serum concentration was reduced to half the concen-
tration at pre-treatment, and the mean concentration
in urine was reduced to about one-fourth of the pre-
treatment concentration (Fig. 4).
Changes in health complaints related to changes in mercury
concentration in serum
Secondary explorative analyses of correlations between
reduction in mercury in serum and reduction in health
complaints 3 years after treatment showed positive but
not signiﬁcant correlations. Pearson correlation coefﬁ-
cients were 0Æ320, 0Æ193 and 0Æ127 for correlations
between reduction in mercury in serum and reduction
in intra-oral, extra-oral and general indices, respec-
tively. Corresponding P-values were 0Æ182, 0Æ428 and
0Æ604 (n = 19), leaving no statistically signiﬁcant sup-
port for mercury as a cause of the complaints.
Adverse events
Seven participants in the treatment group experienced
increased health complaints in connection with
removal of amalgam ﬁllings. Laboratory tests of blood
samples collected within a few days after the treatment
session showed values within reference intervals.
Health complaints reported in connection with amal-
gam removal were gastric pain, pain in joints and
muscles, oral ulcers, sore throat, pain in legs, hands and
feet, dizziness, tachycardia, nausea, diarrhoea, depres-
sion, fatigue, chills, burning sensations in the face, cold
hands, increased blood pressure and submandibular
lymphadenopathy. The increase in complaints was
transient and disappeared within a week or two.
Discussion
The aim of this study was to investigate long-term
changes in subjective health complaints after the
removal of all amalgam ﬁllings in a group of patients
who attributed health complaints to amalgam ﬁllings.
The main ﬁnding was that the long-lasting reductions
Table 4. Repeated measures analysis of changes in health complaints over time. Per-protocol (PP) and intention-to-treat (ITT) repeated
measures analysis of changes in health complaints in the treatment group and the reference group. Mean index scores, standard
deviations (s.d.) and P-values for within-group changes over time are given
n
Questionnaire 1
Pre-treatment
examination
3-month
follow-up
1-year
follow-up
†
3-year
follow-up
‡
P-value* Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Treatment group
Intra-oral index (PP) 18 8Æ6( 6 Æ9) 6Æ6( 3 Æ8) 6Æ7( 4 Æ5) 4Æ7( 5 Æ2) 5Æ2( 3 Æ8) 0Æ026
Intra-oral index (ITT) 20 8Æ4( 6 Æ6) 6Æ8( 3 Æ7) 6Æ4( 4 Æ5) 4Æ8( 5 Æ0) 4Æ9( 3 Æ8) 0Æ015
Extra-oral index (PP) 18 6Æ7( 8 Æ8) 6Æ7( 7 Æ1) 5Æ7( 6 Æ4) 2Æ4( 3 Æ2) 4Æ8( 4 Æ3) 0Æ004
§
Extra-oral index (ITT) 20 6Æ9( 8 Æ4) 6Æ8( 6 Æ8) 5Æ6( 6 Æ3) 2Æ8( 3 Æ8) 4Æ9( 4 Æ4) 0Æ009
§
General index (PP) 18 41Æ4 (16Æ4) 42Æ9 (21Æ3) 39Æ0 (24Æ3) 32Æ1 (19Æ2) 31Æ6 (14Æ5) 0Æ001
General index (ITT) 20 41Æ5 (16Æ0) 42Æ7 (20Æ4) 37Æ9 (23Æ2) 31Æ6 (18Æ5) 31Æ4 (13Æ9) <0Æ001
Reference group
Intra-oral index (PP) 12 11Æ0 (12Æ0) n.a. n.a. 10Æ8 (12Æ8) 15Æ4 (13Æ4) 0Æ245
§
Intra-oral index (ITT) 20 13Æ0 (12Æ0) n.a. n.a. 11Æ3 (12Æ4) 13Æ6 (12Æ2) 0Æ246
§
Extra-oral index (PP) 12 10Æ8 (10Æ6) n.a. n.a. 9Æ4 (11Æ4) 12Æ5 (12Æ6) 0Æ179
§
Extra-oral index (ITT) 20 11Æ0( 9 Æ3) n.a. n.a. 10Æ0 (10Æ0) 11Æ6 (10Æ8) 0Æ259
§
General index (PP) 12 43Æ1 (18Æ1) n.a. n.a. 38Æ3 (23Æ3) 49Æ5 (28Æ5) 0Æ004
§
General index (ITT) 20 47Æ3 (21Æ2) n.a. n.a. 41Æ3 (25Æ2) 49Æ6 (27Æ3) 0Æ004
§
n.a., not applicable.
*P-value from analysis of variance for repeated measures.
†For the reference group, mean index scores from Questionnaire 2 were used.
‡For the reference group, mean index scores from Questionnaire 3 were used.
§Wilks’ Lambda.
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treatment group were signiﬁcantly different from the
change in the reference group, in which there were no
long-lasting reductions.
In the treatment group, intra-oral and general health
complaints were signiﬁcantly reduced 3 years after
completed replacement of amalgam ﬁllings. Reductions
in subjective health complaints after replacement of
amalgam ﬁllings have also been found in previous
studies (24, 25). The reference group received no
intervention, and no improvement in health com-
plaints was found. This is in agreement with data from
patients with health complaints attributed to dental
restorations, mainly dental amalgam, who did not
change the restorations to other materials (8).
It is necessary to consider several factors that may
have inﬂuenced the results. First, there has been a
reduced exposure to mercury in the treatment group.
Previous studies have established that people with
amalgam ﬁllings have higher concentrations of mercury
in blood, plasma, urine and body organs than people
without amalgam ﬁllings (12, 15, 17–19, 31). The
ﬁnding of reduced levels of mercury in serum and urine
in the present study is in agreement with data from
several studies showing that replacement of amalgam
ﬁllings leads to reduced levels of mercury in blood,
plasma and urine (14, 32, 33). Despite this, studies
investigating the relationship between amalgam ﬁllings
and reported health complaints have not found positive
correlations between number of amalgam ﬁllings and
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Fig. 3. Individual index scores from
3-year follow-up and Questionnaire
3 plotted against scores from Ques-
tionnaire 1. Index scores for intra-
oral, extra-oral and general health
complaints from treatment group
(left column) at 3-year follow-up
plotted against index scores before
amalgam removal (Questionnaire 1).
For the reference group (right col-
umn), index scores from Question-
naire 3 were plotted against index
scores from Questionnaire 1. Data
from intention-to-treat analyses (last
value carried forward) are marked
with grey dots in the diagrams.
Results from statistical analyses of
data are given in Table 3.
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there is a causal relationship between amalgam ﬁllings
and health effects, there is not a simple dose–response
relationship between exposure to amalgam ﬁllings and
reported health complaints. In a recently published
study on health effects after removal of amalgam ﬁllings
(34), correlations between amalgam-ﬁlled surfaces and
symptom scores were not statistically signiﬁcant. How-
ever, positive moderate correlations were found
between mercury levels in both plasma and urine and
subjective health complaints, and between reductions in
mercury levels in these media and reductions in
subjective health complaints (34). In the present study,
we found positive but not signiﬁcant correlations
between reduction in mercury concentration in serum
and reductions in subjective health complaints, which
may be in agreement with the analyses presented in
(34). It is possible that some individuals are highly
sensitive to mercury from dental amalgam and may
beneﬁt from reduced exposure (35).
The reference group received no treatment and was
only followed up by questionnaires sent by post. This
makes it difﬁcult to untangle the effects of the general
care associated with amalgam replacement and follow-
ups in the treatment group from the effects of the
amalgam replacement itself. Follow-ups in the treat-
ment group were carried out by health personnel with
both time and motivation to listen to and understand
the patients’ experiences. This may have contributed to
the reduction in reported subjective health complaints
as patient-centred communication has been shown to
be associated with improved patient health outcomes
(36, 37). In addition, participants in the treatment
group no longer had to worry about possible adverse
effects from their amalgam ﬁllings. This may also have
played a part in the reduction in health complaints as
worry has been found to lead to increased monitoring
of complaints, which again may lead to an increased
feeling of ill health (38). Even so, replacement of
amalgam ﬁllings will usually take place in a treatment
context where factors like these are present and, thus,
potentially might inﬂuence the treatment results. Par-
ticipants’ belief in amalgam replacement as an effective
treatment (39) and gratitude in relation to having the
replacement covered by project funds could possibly
have resulted in a response bias towards reporting
reduced health complaints. However, it is not likely
that the participants would remember how they
responded to the scales in the questionnaires several
years ago. Factors mentioned above are linked to
components related to placebo (expectations, condi-
tioning, learning, memory, motivation, somatic focus,
reward, anxiety reduction and meaning), as deﬁned as
a genuine psychobiological event attributable to the
overall therapeutic context (40). In this context, it is
also possible that for some patients, the presence of
amalgam ﬁllings has been associated with a nocebo
effect. Removal of amalgam ﬁllings could therefore
result in a discontinuation of this effect and conse-
quently lead to a reduction in reported health com-
plaints.
Reduction in intra-oral health complaints may have
been inﬂuenced by general effects of the dental treat-
ment received during the amalgam replacement pro-
cess. It does, however, seem unlikely that an effect of
a generally improved dental health should be promi-
nent 3 years after completed replacement, given that
patients with need for complicated dental rehabilitation
were excluded from the treatment group and that the
removed amalgam ﬁllings were described as sound and
well-functioning.
Participants included in this study were recruited
from patients referred to the Dental Biomaterials
Adverse Reaction Unit. Consequently, participants are
not representative of all patients with health complaints
attributed to amalgam ﬁllings. Not all patients with
health complaints attributed to dental amalgam are
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Fig. 4. Mean mercury concentration in serum and urine at pre-
treatment examination and at follow-up after removal of amalgam
ﬁllings. Mean mercury concentration (and s.d.) in serum (nmol
L
)1) and urine (nmol per mmol creatinine) at pre-treatment
examination and at follow-up after removal of amalgam ﬁllings.
Mercury concentration in both serum and urine was signiﬁcantly
reduced after amalgam removal (P <0 Æ001, and P =0 Æ004, respec-
tively).
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by their own dentist or general practitioner or seek help
from practitioners of alternative medicine. Despite lack
of objective signs of adverse reactions to dental amal-
gam, some patients nevertheless have all their amalgam
ﬁllings removed of their own accord because they are
concerned about possible adverse effects of mercury
released from amalgam ﬁllings. The participants
included in this study had not removed all amalgam
ﬁllings, either because they accepted that there were no
indications for amalgam removal or because they did
not have the ﬁnancial means necessary for amalgam
removal. Thus, the treatment group is not directly
comparable with patients who remove amalgam resto-
rations of their own accord (23).
The study was designed as a before-and-after study
with a comparison group (reference group). Compari-
sons between the reference group and the treatment
group must be interpreted with caution. Even though
power calculations showed acceptable power of the
study, the sample size is small and the results should be
considered in context with results from comparable
studies (8, 24, 25, 41). A larger sample size could
provide more precise estimates and less-wide conﬁ-
dence intervals. In addition, there may be unknown
factors that inﬂuence reporting of health complaints
over time in the groups. Another limitation could be
that as the outcome is based on the participants’
reporting of health complaints, the study is open for
response bias in both the treatment group and the
reference group.
In the treatment group, all 20 participants completed
replacement of amalgam ﬁllings, and 19 of the partic-
ipants were able to attend the 3-year follow-up. In the
reference group, seven of the 20 participants were lost
to follow-up or excluded because of completed removal
of amalgam ﬁllings (Fig. 1). The response rate in the
reference group was inﬂuenced by the fact that only
two reminders, by letter, is allowed by the Regional
Committee for Medical Research Ethics. This is in line
with the standards used by the Norwegian National
Committee for Medical and Health Research Ethics. As
there were no major differences between the results
from the per-protocol analyses and the intention-to-
treat analyses, we assume the potential bias from
non-random dropout of participants or exclusion of
‘protocol violators’ (participants in the reference group
who removed amalgam during the study) had no major
impact on the result.
Exclusion criteria were initially not applied in the
reference group. The clinical examination necessary to
fully apply these criteria could potentially lead to a
renewed focus on amalgam ﬁllings as a possible cause of
ill health, thus increasing the risk of participants in the
reference group initiating amalgam removal of their
own accord. As no intervention was planned for the
reference group, the participants were not asked to
undergo a clinical examination. The patients excluded
from the treatment group were, based on their
responses to Questionnaire 1, quite similar to the
treatment group and the reference group, with the
exception of per cent on sick leave or disability pension.
For this variable, exclusion of the 10 patients resulted in
a more equal occupational status for the treatment
group and the reference group (Table 2). Changes in
health complaints in the treatment group were com-
pared with changes in both the initial reference group
and changes in the reference group after post hoc
application of exclusion criteria. No major differences
were found between the two comparisons. However, as
there was no clinical pre-treatment examination of
patients in the reference group, there could still be
differences between the groups. The bias from differ-
ences between the groups at study start is expected to
be limited.
Treatment of patients with subjective health com-
plaints attributed to amalgam ﬁllings should only be
considered after a thorough medical and dental exam-
ination has been carried out and other causes for the
complaints have been eliminated or adequately treated
(42). The results from the present study, and other
studies investigating the effects of amalgam replace-
ment, indicate that replacement of amalgam ﬁllings is
associated with reductions in subjective health com-
plaints at group level. The mechanisms behind this are
not known, and other treatment options than amalgam
replacement should also be considered. In a recent
randomised clinical trial, all investigated treatments
(amalgam removal, amalgam removal plus biological
detoxiﬁcation and health promotion without amalgam
removal) resulted in clinically relevant reductions in
health complaints (25). When considering replacement
of intact amalgam ﬁllings, potential beneﬁts must be
balanced with risks associated with the dental treatment
(e.g. tooth fractures or endodontic complications).
When removing amalgam ﬁllings, measures should be
taken in order to minimise exposure to mercury for both
patients and dental personnel (29, 42).
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replacement of amalgam ﬁllings was associated with
reductions in subjective health complaints at group
level. The mechanisms behind this remain to be
identiﬁed. Reduced exposure to mercury, patient-cen-
tred treatment and follow-ups, and elimination of
worry are factors that may have inﬂuenced the results.
In this study, we investigated changes in index scores.
More knowledge is needed about changes in speciﬁc
complaints included in the index scores after replace-
ment of amalgam ﬁllings, and a characterisation of the
treatment group in this respect is warranted.
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